Trial stopped early (110 of 815 planned randomised) in resected stage IIB/IIC BRAF V600E/K melanoma: on encorafenib+binimetinib vs placebo, 24% of 54 treated had grade ≥3 treatment-related AEs and 33% stopped for AEs. Secondary 12-month RFS was 86% vs 70%.
RCTn = 110
van Akkooi et al. primary analysis of the RANDOMIZED eortc-2139/columbus-ad trial: Adjuvant encorafenib and binimetinib versus placebo in high-risk stage II BRAF-V600E/K melanoma